The physicians at Long Island and Queens Vitreoretinal Consultants are committed to offering our patients the best care for their eye conditions. To help us achieve this goal, we actively participate in clinical trials to help develop new and better therapies.
Studies Currently Enrolling:
Ranibizumab (Lucentis®) For the treatment of Diabetic Macular Edema - Ongoing. No long enrolling.
CRVO-IST – Evaluating the treatment of macular edema due to retinal vein occlusions with Ozurdex in combination with anti- VEGF
CRAVE- Evaluating the treatment of macular edema due to retinal vein occlusions with Lucentis® vs. Avastin®
SEE Study- For the treatment wet AMD
Coming Soon:
Dexamethasone (DEX PS DDS) vs. Ranibizumab (Lucentis®) - A study comparing the safety and efficacy for the treatment of Diabetic Macular Edema (DME)
Past Experience:
Visudyne® - for wet AMD (VAM Study and VERITAS Study)
Lucentis® (Ranibizumab) for wet AMD (SAILOR Study and FOCUS Study)
- for Retinal Vein Occlusion (BRAVO)
Macugen® - for wet AMD
Posurdex® - for wet AMD
PK-C ß inhibitor for Diabetic Retinopathy
Vitrase® (hyaluronidase) for severe vitreous hemorrhage in Diabetic Retinopathy
Retaane® - for wet AMD
- for prevention of wet AMD in people at high risk
Squalamine Lactate for wet AMD
For more information about clinical trials contact our Study Coordinator,
Marianne Schlameuss, RN, at 516-466-0390 ext. 222 (Great Neck),
631-234-5666 ext. 118 (Hauppauge) Or email at research.livr@gmail.com
|
